

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

PE/Cyanine7 anti-human CD11b

RRID:AB_830644

Type: Antibody

Proper Citation

BioLegend Cat# 301322, RRID:AB_830644

Antibody Information

URL: http://antibodyregistry.org/AB_830644

Proper Citation: BioLegend Cat# 301322, RRID:AB_830644

Target Antigen: CD11b

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone ICRF44

Antibody ID: AB_830644

Vendor: BioLegend

Catalog Number: 301322

Alternative Catalog Numbers: 301321

Record Creation Time: 20250820T034251+0000

Record Last Update: 20250820T165945+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD11b.

No alerts have been found for PE/Cyanine7 anti-human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages. eLife, 13.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. Cell reports, 43(2), 113767.

Pettinella F, et al. (2024) Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell reports. Medicine, 5(2), 101380.

Lanman NA, et al. (2024) Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. Frontiers in immunology, 15, 1494476.

Wang H, et al. (2023) Multi-omics blood atlas reveals unique features of immune and platelet responses to SARS-CoV-2 Omicron breakthrough infection. Immunity, 56(6), 1410.

Liu X, et al. (2022) CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. Cancer cell, 40(11), 1341.

Vijayakumar B, et al. (2022) Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity, 55(3), 542.

Dannenmann B, et al. (2021) iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. Cell stem cell, 28(5), 906.

Jin Y, et al. (2019) Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nature communications, 10(1), 391.

Rotolo A, et al. (2018) Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. Cancer cell, 34(4), 596.

Sun J, et al. (2018) SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. *Cell stem cell*, 23(3), 355.